Amgen’s Tepezza is facing a broader thyroid eye disease treatment landscape after Viridian Therapeutics’ Lumvoa became another approved option, shifting attention toward how physicians may weigh evidence, safety, treatment burden and patient fit. Dr. Raymond Douglas, MD, PhD, who served as principal investigator in the international Tepezza trials that supported its United States Food and Drug Administration approval, told PharmaDeviceNews that more treatment options are positive for patients, but require careful discussion of the risks, benefits, clinical data and real-world experience behind each therapy.
The comments follow PharmaDeviceNews’ earlier coverage of Lumvoa’s approval for thyroid eye disease, a development that introduced another insulin-like growth factor-1 receptor-targeted medicine into a treatment category long led by Tepezza. The new landscape does not create a simple winner-versus-loser comparison because there are no direct head-to-head clinical trials between Tepezza and Lumvoa, but it does make the practical question of treatment selection more important for clinicians, patients, payers and industry observers.
Dr. Douglas is a board-certified aesthetic and reconstructive oculoplastic surgeon based in Beverly Hills, California. According to background information shared with PharmaDeviceNews, he is also a professor at Cedars-Sinai Medical Center in Los Angeles, where he heads orbital and thyroid eye disease programmes. His work focuses on oculoplastic surgery, thyroid eye disease treatment and functional restoration for patients affected by the autoimmune eye disorder.
Why Lumvoa approval changes the treatment discussion around Amgen’s Tepezza
Lumvoa’s approval changes the thyroid eye disease market because physicians and patients now have more than one approved treatment option for a condition that can affect appearance, vision, daily function and quality of life. For Amgen, that means Tepezza is no longer being evaluated only as the first approved therapy in the field. It is now being discussed alongside another labelled option that may influence how treatment burden, evidence history and patient goals are weighed in practice.
Dr. Douglas said he has treated patients with Tepezza since it was approved six years ago and expects the medicine to remain an important option that he offers to patients. He also said both Tepezza and Lumvoa are approved for active and chronic thyroid eye disease, making it important for physicians to help patients understand the risks, benefits, clinical data and real-world experience behind each therapy.
That framing keeps the discussion clinically grounded. Lumvoa’s arrival gives patients more choice, but it does not remove the need for careful interpretation of each evidence package. Tepezza still brings established physician familiarity and real-world use, while Lumvoa brings a new approved option into a disease area where patients may have different symptom patterns, risk factors and treatment priorities.
The immediate implication is that thyroid eye disease treatment may move away from a single-product conversation and toward a more individualised discussion. Physicians may need to explain not only what each therapy showed in clinical development, but also how its safety profile, durability, administration schedule and accumulated experience apply to the patient being treated.
How should physicians read Tepezza and Lumvoa data without head-to-head trials?
The absence of direct head-to-head trial data between Tepezza and Lumvoa is one of the most important limits in the current treatment debate. Dr. Douglas said cross-trial comparisons should be interpreted with caution because study designs, patient populations, inclusion and exclusion criteria and follow-up periods may differ.
That caution matters because the market will inevitably compare the two medicines. Patients may ask about the number of infusions and treatment duration. Physicians may examine response measures, durability and safety. Payers may assess the available evidence in relation to coverage, cost and appropriate use. Yet separate clinical programmes cannot be treated as if they produced a direct ranking.
Dr. Douglas said both medicines have shown strong benefits and defined safety risks. He also noted that Tepezza benefits from having been approved for six years, giving it a longer period of clinical use and real-world experience.
For Amgen, that history is a meaningful part of Tepezza’s position. For Viridian Therapeutics, Lumvoa’s opportunity is to build clinical confidence after approval while competing in a market where physician awareness already exists. For clinicians, the more immediate task is narrower and more practical: to interpret the available evidence responsibly without overstating what separate trials can prove.
Why patient symptoms may matter more than any single thyroid eye disease endpoint
Dr. Douglas said no two thyroid eye disease journeys are alike. Some patients present with active disease, while others have more stable or longer-standing disease. Some are most affected by proptosis, while others may be more troubled by diplopia or the broader effect of the disorder on quality of life.
That variation is clinically important because treatment success in routine practice may not be captured by one endpoint alone. Proptosis is a visible and measurable feature of thyroid eye disease. Diplopia can interfere with reading, driving, mobility and work. Quality of life may be harder to quantify, but it often determines whether patients feel that treatment has made a meaningful difference.
Dr. Douglas said that when assessing whether a treatment has worked, he looks at the individual patient’s needs and the broader picture of response, including symptom improvement, quality of life and durability. That view fits the current moment in the market, where physicians may increasingly need to match treatment evidence to specific patient concerns rather than relying on a single headline measure.
This is also where the competitive discussion becomes more complex. A therapy may appear attractive because of its administration schedule, while another may carry greater physician familiarity or longer follow-up experience. Neither factor alone fully answers the clinical question. The more relevant issue is whether the treatment choice addresses what the patient most needs to improve, while maintaining an acceptable safety and monitoring profile.
How active and chronic TED patients may shape treatment selection
Disease activity and duration remain important considerations in thyroid eye disease, but Dr. Douglas said they are only part of the broader clinical picture. He said the disease can vary considerably from one person to another, and emerging real-world evidence suggests it may not always follow a predictable progression from an active phase to a stable chronic phase.
That point is relevant because treatment decisions have often been framed around whether a patient has active inflammatory disease or longer-standing chronic symptoms. If the course is less predictable in real-world practice, physicians may place greater weight on symptoms, functional burden and disease impact rather than relying too heavily on a rigid phase-based model.
Dr. Douglas said physicians should evaluate each patient’s signs, symptoms, disease burden and impact on daily life, along with activity and duration. He also said the full body of clinical and real-world evidence supporting each treatment option should be considered when deciding the most appropriate approach for an individual patient.
For companies in this field, that creates a broader commercial challenge. Messaging around active and chronic thyroid eye disease must remain precise, because labels and trial populations matter. At the same time, market adoption may depend on how well manufacturers support physician education across a range of patient presentations, including individuals who do not fit neatly into simplified disease-stage categories.
Why treatment burden matters but may not decide Tepezza versus Lumvoa choice
Treatment burden is likely to remain one of the most visible areas of discussion after Lumvoa’s approval. Infusion number, treatment duration, visit scheduling and travel requirements can all matter to patients, especially those balancing care with work, family responsibilities or long-distance access to specialist centres.
Dr. Douglas said treatment burden is certainly part of the conversation, but only one of several factors physicians consider when making treatment decisions. He said efficacy, durability, safety and the patient’s overall treatment goals all play an important role in determining the most appropriate approach.
That distinction is important for both Amgen and Viridian Therapeutics. Lumvoa’s treatment schedule may be commercially relevant, but convenience alone is unlikely to settle the treatment decision. Tepezza’s longer clinical history may support physician confidence, but real-world experience must still be weighed against individual patient needs, label information and practical considerations.
The commercial debate may therefore be less simple than infusion count versus incumbent status. Payers may consider course cost, monitoring requirements, retreatment questions and available clinical evidence. Physicians may focus on symptom burden, comorbidities and patient preference. Patients may look for the therapy that offers a credible chance of meaningful improvement while fitting the realities of their lives.
What safety monitoring means for IGF-1R-targeted thyroid eye disease therapy
Safety remains central to the thyroid eye disease treatment conversation because insulin-like growth factor-1 receptor-targeted therapies are used in patients who may have complex autoimmune disease, thyroid dysfunction, diabetes risk or other medical considerations. Dr. Douglas said physicians should review the product label and discuss potential risks and benefits with patients before initiating treatment.
He identified hearing-related adverse events as an important consideration with IGF-1R-targeted therapies and said they should be closely monitored to minimise the risk of long-term consequences. He also said hyperglycemia should be considered, particularly in patients with pre-existing diabetes.
The implication is that baseline assessment and monitoring are part of treatment selection, not administrative details. A patient’s hearing status, diabetes history, ability to attend follow-up visits and broader risk profile may all influence how physicians approach therapy.
For manufacturers, safety education will remain important as the market expands. Wider use may bring treatment into more varied clinical settings, increasing the need for clear monitoring pathways and coordination between specialists. For patients, the existence of more options is valuable only if treatment decisions remain anchored in a careful benefit-risk discussion.
Why Tepezza’s real-world experience remains central to Amgen’s position
Tepezza’s established position gives Amgen a competitive argument that extends beyond first-mover status. Dr. Douglas said real-world experience is extremely valuable because it helps clinicians understand how a treatment performs in a broad patient population outside the controlled setting of a clinical trial.
He said Tepezza is supported by five published global clinical trials, six years of real-world experience and more than 25,000 patients treated, with additional studies continuing. He also said his group has prescribed a large volume of Tepezza and is familiar with its effects. At the same time, he said he is optimistic that Lumvoa will offer patients additional options in the future.
That balance is useful because it avoids a simplistic competitive claim. Dr. Douglas is clearly highlighting Tepezza’s accumulated evidence and experience, but he is not dismissing the value of another approved therapy. His comments instead point to a market where physicians may weigh established use and newer choice together.
For Amgen, the challenge is to maintain confidence in Tepezza as physicians encounter another labelled alternative. For Viridian Therapeutics, the task is to translate approval into physician familiarity, payer access and real-world use. In both cases, the treatment category is moving from regulatory novelty to commercial execution and evidence-based differentiation.
Which thyroid eye disease patients still risk being missed despite more approved therapies?
More approved medicines do not automatically solve the care gap in thyroid eye disease. Dr. Douglas said the condition remains a complex autoimmune disease that can be difficult to diagnose and manage. Many patients still face challenges across the care journey, including diagnosis, referral, access to treatment and coordination among specialists.
He said some patients may remain undiagnosed, experience delays in referral to thyroid eye disease specialists, or consider their disease too moderate to realise they may be eligible for treatment. That observation is important because the next phase of market growth may depend not only on competition between Tepezza and Lumvoa, but also on whether more patients are identified and referred earlier.
Better education could help physicians recognise thyroid eye disease sooner and connect patients with appropriate care. Because the condition can involve ophthalmology, endocrinology and other specialties, coordinated referral pathways may be as important as product availability.
For industry observers, this is where the commercial opportunity and clinical need intersect. If additional approved options increase awareness and specialist engagement, the market may expand beyond switching patients between therapies. If diagnosis and referral remain fragmented, patients may continue to face delays even in a more competitive treatment landscape.
How the next phase of TED care will test evidence, access and physician confidence
Lumvoa’s approval has widened the thyroid eye disease treatment field, but the practical test is still ahead. Tepezza remains the established therapy with years of use behind it. Lumvoa brings another approved option and gives physicians a broader set of factors to discuss with patients.
Dr. Douglas’s responses suggest that the next phase will not be decided by one measure. Physicians may weigh proptosis, diplopia, quality of life, durability, safety, administration burden, patient goals and evidence maturity together. The absence of head-to-head data means separate trial results must be read carefully, especially when treatment choices involve patients with different disease histories and symptom priorities.
For Amgen, the post-Lumvoa period will test how strongly Tepezza’s evidence base and real-world experience continue to influence prescribing decisions. For Viridian Therapeutics, approval is only the starting point for building durable market confidence. For patients, the most important change is that the conversation can now move from limited choice toward a more individualised discussion of which approved therapy best fits the clinical situation.
